Bette Caan to Medroxyprogesterone Acetate
This is a "connection" page, showing publications Bette Caan has written about Medroxyprogesterone Acetate.
Connection Strength
0.782
-
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20; 304(15):1684-92.
Score: 0.353
-
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004 Mar 04; 350(10):991-1004.
Score: 0.223
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17; 288(3):321-33.
Score: 0.100
-
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008 Mar 05; 299(9):1036-45.
Score: 0.074
-
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006 Sep 20; 55(2):103-15.
Score: 0.016
-
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006 Apr 01; 163(7):589-99.
Score: 0.016